(Editor’s Note: The author of the following opinion column is affiliated with AGIF, the American Growth and Innovation Forum.)
Recently, the Trump administration announced a series of agreements aimed at dramatically lowering the price of in vitro fertilization, typically referred to as IVF, in a huge win for American families.
IVF, a widely used yet costly fertility treatment, was a key topic during the 2024 election cycle. A single IVF treatment cycle can cost tens of thousands of dollars, and many couples often require more than one cycle for a successful pregnancy.
Thankfully, help is on the way.
With the new agreements between the Trump administration and leading American healthcare companies, both access to and affordability for IVF treatments will improve nationally.
The move delivers upon one of Trump’s campaign promises to make IVF more accessible for American families, a pledge he doubled down on through an executive order issued in February of this year.
Importantly, the administration did not impose these changes through heavy-handed regulation or government mandates.
Instead, the president partnered with large American businesses that are uniquely equipped to turn his promise on IVF into a reality — an approach that exemplifies how government should collaborate with business to solve high-cost challenges that require both innovation and scale.
At the American Growth and Innovation Forum (AGIF), we champion the ability of American enterprise to make life more affordable.
This IVF initiative is a perfect example of how, when the private and public sectors stand shoulder to shoulder, they improve lives by lowering costs, expanding access, and leading the world in progress.
The agreement is a deal between the administration and drug manufacturer EMD Serono, which produces three of the most common IVF treatments, and specialty pharmacy chains CVS Specialty Pharmacy and Express Scripts’ Freedom Fertility.
Together, these companies account for dispensing more than 80% of Gonal-f, a popular fertility treatment, ensuring the effort has the proper scale to make an impact.
According to their press release, EMD Serono has pledged to offer three of the leading IVF therapies, including Gonal-f, Ovidrel, and Cetrotide, to patients at an 84% discount off list prices.
CVS Health, meanwhile, will leverage its unique capabilities, including specialty pharmacy services and claims support, to facilitate IVF access both reliably and at scale.
In a statement, CVS Health vowed to support simpler access to more affordable fertility treatments across their 9,000 community pharmacies.
Additionally, the release outlines how their specialty pharmacy has a team of dedicated pharmacists focused on fertility treatments, who can help people understand their fertility benefit and assess their financial options.
Timing is key for the effectiveness of fertility, so expediting the pharmacy process is important for successful treatment.
Officials estimate the overall cost of IVF treatment, when combining medication savings with pharmacy service efficiencies, will drop by about $2,200 per treatment cycle.
Joining President Trump in the Oval Office for the announcement was U.S. Sen. Katie Britt, R-Ala., a longtime champion of IVF and an advocate for increased affordability.
According to a subsequently posted press release, the senator has been a tireless advocate for creating more affordable and accessible pathways for potential and current parents.
In this instance, creating affordable and accessible pathways for parents are the result of the progress and innovation provided by American business.
In truth, this pathway is more common than many lawmakers may care to admit, lawmakers, such as Sen. Britt and others, should build on this strategy to improve conditions for Americans.
President Trump, in negotiating this breakthrough for hopeful parents, sets an example for good governance.
When government partners alongside, rather than punishes, big businesses, the result is affordable and accessible solutions for American families delivered at scale.
Diana London is a seasoned political strategist and commentator with over five years of experience on Capitol Hill. Currently a Newsmax columnist, Diana is President and Co-Founder of Ford & London Global Strategies, and Vice President of X Capital Investments. She also serves as CEO of The Secret Weapon Agency, specializing in crisis communications and public relations. She works on advancing conservative initiatives and empowering diverse communities as well as championing criminal justice reform. She is also the executive director of the American Growth and Innovation Forum (AGIF). Read Diana London’s Reports — More Here.
© 2025 Newsmax. All rights reserved.
